Press

Press Release

MindBio Issues Restricted Stock Units

Vancouver, British Columbia –TheNewswire –May 7, 2025– MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, has today issued Restricted Stock Units (RSUs) to certain directors and individuals that work for the Company. On May 2, 2025, the Company’s Board of Directors approved the issuance…

Optimi-Health

Optimi Health Obtains U.S. FDA Drug Establishment Registration

Vancouver, British Columbia–(Newsfile Corp. – May 5, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings and compliant supply into the United States. According to…

Mydecine Innovations Group

Mydecine Innovations Group Provides Update on Annual Financial Statements

Vancouver, British Columbia – TheNewswire – May 15, 2025 — Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the “MCTO”) by the British Columbia Securities Commission under National Policy 12-203 – Management Cease…

Psyence

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

New York, New York–(Newsfile Corp. – May 1, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company’s issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a…